Woman staring into distance

The only Fc-free biologic with no to minimal placental transfer*1-3, 5-10

When considering a biologic for eligible women with moderate severe active RA, active PsA, moderate to severe PsO or severe active axSpA, think Cimzia (certolizumab pegol)4

*In-vivo, ex-vivo, animal studies, and one post-marketing study of 14 infants suggest low to negligible level of placental transfer of Cimzia. The clinical significance of low levels certolizumab pegol for infants is unknown

Orbit 360 enabled

Cimzia is indicated for the treatment of4:

  • Moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate.
  • Severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.
  • Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.
  • Active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
  • Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

The use of adequate contraception should be considered for women of childbearing potential who have been prescribed Cimzia. For women planning pregnancy, continued contraception may be considered for 5 months after the last Cimzia dose due to its elimination rate. Cimzia should only be used during pregnancy if clinically needed.4

Please refer to the SmPC for further information.

Orbit 360 enabled

Find the information you are looking for

Access these pages for detailed data and resources related to each of Cimzia's indications
Order patient materials
Select contact us to get in touch or to set up a meeting with a UCB representative or a member of the UCB Medical Information team
Orbit 360 enabled



Request patient materials

UCB connect offers a large catalogue of patient materials available to order and use within your clinics

UCB have a wealth of patient materials available for you to order for use within your clinics. Please find below the materials available along with their order limits. Once you complete your order, a member of the UCB Cares team will be in touch with you via the details you have registered with, to organise delivery of your materials. You will need to be logged in to request these materials.

If you have any queries, please contact us.

Cimzia patient guide

Cimzia patient guide

This resource can be used with your Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondyloarthritis (axial SpA) or Plaque Psoriasis (PsO) patients. The guide includes all your patients need to know about their treatment with Cimzia as well as useful tools, so they can start with clear treatment expectations and goals in mind.



  1. Gordon K et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021: 184:652-662.
  2. Blauvelt A et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III randomised placebo-controlled studies. Br J Dermatol. 2021:640-651.
  3. Curtis JR et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open 2019;5:e000942.
  4. CIMZIA® Summary of product characteristics. Available at https://www.medicines.org.uk/emc/product/4450/smpc [Accessed December 2022]
  5. Carron P, Lambert B, Van Praet L, et al. Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. RMD Open 2016;2:e000265.
  6. Pasut G. Pegylation Of Biological Molecules And Potential Benefits: Pharmacological Properties Of Certolizumab Pegol. BioDrugs 2014;28 Suppl 1:S15–23.
  7. Porter C, Armstrong- Fisher S, Kopotsha T, et al. Certolizumab Pegol Does Not Bind The Neonatal Fc Receptor (FcRn): Consequences For FcRn-Mediated In Vitro Transcytosis And Ex Vivo Human Placental Transfer. J Reprod Immunol 2016;116:7–12.
  8. Roopenian DC, Akilesh S. FcRn: The Neonatal Fc Receptor Comes Of Age. Nat Rev Immunol 2007;7:715–725.
  9. Mariette, X. et al., 2017. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study. Annals of the Rheumatic Diseases, 76, pp.57-58.
  10. Clowse M et al. Pharmacovigilance pregnancy data in a large population of patients with inflammatory disease exposed to certolizumab pegol. Ther Adv Musculoskel Dis 2022;14:1-18.
Orbit 360 enabled
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: December 2022